Lupin’s - US subsidiary, Lupin Pharmaceuticals, has launched its generic Gatifloxacin Ophthalmic Solution in the US, 0.5%. Lupin had earlier received final approval from the United States Food and Drugs Administration (US FDA) to market a generic version Allergan Inc's Zymaxid Ophthalmic Solution, 0.5%.
Lupin's Gatifloxacin Ophthalmic solution 0.5% is the generic equivalent of Zymaxid Ophthalmic Solution of Allergan and is indicated for the treatment of bacterial conjunctivitis. Zymaxid Ophthalmic Solution, 0.5%, had annual U.S. sales of approximately $ 62.3 million (IMS MAT Jun 2013). Lupin was the first applicant to file an ANDA for Zymaxid Ophthalmic Solution and as such will be entitled to 180 days of marketing exclusivity.
Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally.
